Clinical Trials | September 17, 2025
Enveric clears FDA feedback milestone, prepares IND submission for EB-003
IND application for EB-003 expected in early 2026
IND application for EB-003 expected in early 2026
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Subscribe To Our Newsletter & Stay Updated
